Huntington's Disease (HD) is dominantly inherited neurodegenerative disorder manifested by psychiatric, cognitive and motor symptoms typically starting in mid life and progressing toward death. HD is caused by an expansion of a polyglutamine tract in tile huntingtin protein. The number of diseases caused by polyglutamine expansions continues to, grow and a common mechanism could underlie these disorders. One hypothesis suggests that acting within the nucleus, polyglutamine expansion results in aberrant interactions with nuclear proteins, thereby leading to transcriptional dysregulation. Gene expression arrays on DNA microchips have showed that the scope of transcriptional changes in transgenic HD mice involves different groups of genes, including neurotransmitter receptors. Interestingly, when the known regulatory sequences of these genes were examined it became apparent that they contained binding sites for transcription factor Spl, suggesting that huntingtin may interfere with Spl-mediated transcription. Our preliminary data demonstrate that both normal and mutant huntingtin interact with Spl, whereas only mutant huntingtin significantly inhibits Splmediated transcription of dopamine receptors. In addition, we showed that Spl and its coactivators play a critical role in huntingtin-induced neuronal toxicity. In this work we propose to use our model to accomplish the following Specific Aims: 1) Characterize the specific components of transcriptional machinery required by normal or mutant huntingtin to regulate Spl-mediated expression of dopamine receptors in HD. 2) Examine activity and expression levels of Spl and related factors in transgenic and human HI) brain 3) Determine whether interference by drugs such as mithramycin and HDAC inhibitors with ,Spl-mediated gene transcription may protect against mutant huntingtin. Completion of these aims should reveal new insights into general mechanisms of neurodegeneration and lead to the identification of potential molecular targets for new HI) therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS045242-05
Application #
7553902
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
5
Fiscal Year
2007
Total Cost
$200,908
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Tourette, Cendrine; Farina, Francesca; Vazquez-Manrique, Rafael P et al. (2014) The Wnt receptor Ryk reduces neuronal and cell survival capacity by repressing FOXO activity during the early phases of mutant huntingtin pathogenicity. PLoS Biol 12:e1001895
McFarland, Karen N; Das, Sudeshna; Sun, Ting Ting et al. (2013) Genome-wide increase in histone H2A ubiquitylation in a mouse model of Huntington's disease. J Huntingtons Dis 2:263-77
Taylor, David M; Moser, Roger; Regulier, Etienne et al. (2013) MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition. J Neurosci 33:2313-25
McFarland, Karen N; Das, Sudeshna; Sun, Ting Ting et al. (2012) Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease. PLoS One 7:e41423
Sleiman, Sama F; Langley, Brett C; Basso, Manuela et al. (2011) Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci 31:6858-70
Hu, Yi; Chopra, Vanita; Chopra, Raman et al. (2011) Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci U S A 108:17141-6
Kim, Jinho; Amante, Daniel J; Moody, Jennifer P et al. (2010) Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochim Biophys Acta 1802:673-81
Ebbel, Erika N; Leymarie, Nancy; Schiavo, Susan et al. (2010) Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry. Anal Biochem 399:152-61
Zucker, Birgit; Kama, Jibrin A; Kuhn, Alexandre et al. (2010) Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease. J Neuropathol Exp Neurol 69:880-95
Benn, Caroline L; Luthi-Carter, Ruth; Kuhn, Alexandre et al. (2010) Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease. J Neuropathol Exp Neurol 69:817-27

Showing the most recent 10 out of 65 publications